VARICELLA VACCINe  (var-i-cel'la) 
  Varivax Classifications: vaccine, viral;  Therapeutic: viral vaccine Prototype: Hepatitis B Pregnancy Category: C
  |  
 
 
 
 
 Availability
 
 1350 PFU/vial
 
 Action
 
 A live attenuated vaccine that acts against both chickenpox and shingles, both of which are caused by Varicella zoster infection.
 
 Therapeutic Effect
 
 Effective in protecting healthy children and adults from varicella.
 
 Uses
 
 Vaccination against varicella in individuals ≥12 mo.
 
 Contraindications
 
 Hypersensitivity to any component of the vaccine; history of anaphylactoid reaction to neomycin; individuals with blood 
 dyscrasia, leukemia, lymphomas, bone marrow or lymphatic system malignancies, concomitant immunosuppression therapy; individuals 
 with primary or acquired immunodeficient states; active untreated tuberculosis; any febrile respiratory illness or other 
 febrile infections; pregnancy (category C); children <1 y. 
 
 
 Cautious Use
 
 Acute lymphoblastic leukemia in remission; IgA deficiency; lactation.
 
 Route & Dosage
 
  
  
 Varicella Protection Adult: SC Primary immunization of 0.5 mL followed by 0.5 mL 48 wk after first dose, may need to revaccinate 3 mo after initial 
 series if patient fails to seroconvert Child (12 mo12 y): SC Single dose of 0.5 mL
  |  
 
 
 
 
 
Administration
Subcutaneous 
 - Reconstitute vaccine with 0.7 mL of supplied diluent; gently agitate the vial to mix. Withdraw entire contents of vial (0.5 
 mL) into syringe for injection. Change needle on syringe and administer immediately or within 30 min of reconstitution. 
 
  
 - Give SC into the outer aspect of the deltoid. Exercise caution not to inject IV.
  
 - Store powder vaccine in frost-free freezer at 15° C (+5° F) or colder. Store diluent separately at room temperature 
 or in the refrigerator. 
 
  
 
 
 Adverse Effects (≥1%)
CNS: Headache, fever. 
Hematologic: Mild thrombocytopenia. 
Skin: Redness, swelling, or rash at injection site. Other: Herpes zoster infection (rare). 
 
Interactions
Drug: Acyclovir decreases vaccine's effectiveness. It is recommended that 
yellow fever vaccine be given at least 1 mo apart from varicella or any other live virus vaccine. Avoid 
salicylates for 6 wk after vaccination to decrease risk of developing Reye's syndrome. 
 
Pharmacokinetics
Onset: Seroconversion approximately 42 d after vaccination. 
Duration: >510 y in healthy children. 
Distribution: Crosses placenta; distributed into breast milk. 
 
Nursing Implications
 
 Assessment & Drug Effects
 
  
 - Withhold vaccine and notify physician if patient has a history of hypersensitivity to neomycin or a current febrile infection.
  
 - Monitor for signs and symptoms of hypersensitivity (see Appendix F) and administer epinephrine if an anaphylactoid reaction 
 occurs. 
 
  
 
 
 Patient & Family Education
 
  
 - Avoid use of salicylates (e.g., acetylsalicylic acid) for 6 wk after vaccination, especially with children and adolescents.
  
 - Notify physician about all adverse reactions (i.e., fever, rash, respiratory illness).